Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Annunziata Website

Christina M. Annunziata, M.D., Ph.D.

Selected Publications

1)  Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Kuehl WM, Staudt LM.
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Cancer Cell. 12: 115-30, 2007.
[Journal]
2)  Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC.
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer.
Cancer. 116: 3276-84, 2010.
[Journal]
3)  Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM.
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.
Cancer Res. 70: 4005-14, 2010.
[Journal]
4)  Hsu S, Kim M, Hernandez L, Grajales V, Noonan A, Anver M, Davidson B, Annunziata CM.
IKK-e coordinates invasion and metastasis of ovarian cancer.
Cancer Res. 72: 5494-504, 2012.
[Journal]
5)  Szabova L, Bupp S, Kamal M, Householder DB, Hernandez L, Schlomer JJ, Baran ML, Yi M, Stephens RM, Annunziata CM, Martin PL, Van Dyke TA, Ohler ZW, Difilippantonio S.
Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
PLoS ONE. 9: e95649, 2014.
[Journal]
6)  Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses.
J. Natl. Cancer Inst. 106, 2014.
[Journal]
7)  House CD, Hernandez L, Annunziata CM.
Recent Technological Advances in Using Mouse Models to Study Ovarian Cancer.
Front Oncol. 4: 26, 2014.
[Journal]
8)  Hays JL, Kim G, Walker A, Annunziata CM, Lee JM, Squires J, Houston N, Steinberg SM, Kohn EC.
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.
Mol Clin Oncol. 1: 565-569, 2013.
[Journal]
9)  Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
Br. J. Cancer. 109: 1072-8, 2013.
[Journal]
10)  Lee JM, Hays JL, Noonan AM, Squires J, Minasian L, Annunziata C, Wood BJ, Yu M, Calvo KR, Houston N, Azad N, Kohn EC.
Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.
Cancer. 119: 1357-64, 2013.
[Journal]
11)  Cherry BM, Costello R, Zingone A, Burris J, Korde N, Manasanch E, Kwok M, Annunziata C, Roschewski MJ, Engels EA, Landgren O.
Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age.
Am. J. Hematol. 88: 89-92, 2013.
[Journal]
12)  Annunziata CM, Kohn EC.
Novel facts about FAK: new connections to drug resistance?.
J. Natl. Cancer Inst. 105: 1430-1, 2013.
[Journal]
13)  Azad N, Yu M, Davidson B, Choyke P, Chen CC, Wood BJ, Venkatesan A, Henning R, Calvo K, Minasian L, Edelman DC, Meltzer P, Steinberg SM, Annunziata CM, Kohn EC.
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
Mol. Cell Proteomics. 12: 1621-31, 2013.
[Journal]
14)  Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, Hetland T, Kohn EC.
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome.
Cancer. 118: 1543-53, 2012.
[Journal]
15)  Weng MT, Lee JH, Wei SC, Li Q, Shahamatdar S, Hsu D, Schetter AJ, Swatkoski S, Mannan P, Garfield S, Gucek M, Kim MK, Annunziata CM, Creighton CJ, Emanuele MJ, Harris CC, Sheu JC, Giaccone G, Luo J.
Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells.
Proc. Natl. Acad. Sci. U.S.A. 109: E3659-67, 2012.
[Journal]
16)  Annunziata CM, Kohn EC, Lorusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R.
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.
Invest New Drugs. 31: 77-84, 2012.
[Journal]
17)  Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, Hurt EM, Shaffer AL, Kuehl WM, Staudt LM.
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.
Blood. 117: 2396-404, 2011.
[Journal]
18)  Driscoll JJ, Burris J, Annunziata CM.
Targeting the Proteasome With Bortezomib in Multiple Myeloma: Update on Therapeutic Benefit as an Upfront Single Agent, Induction Regimen for Stem-Cell Transplantation and as Maintenance Therapy.
Am J Ther. 19: 133-44, 2011.
[Journal]
19)  Annunziata CM, Birrer MJ.
CD157 in ovarian carcinoma: how does it help us?.
J. Natl. Cancer Inst. 102: 1104-5, 2010.
[Journal]
20)  Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, Squires J, Houston N, Kohn EC.
Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
Br. J. Cancer. 102: 495-9, 2010.
[Journal]
21)  Annunziata C, Bates S.
PARP inhibitors in BRCA1/BRCA2 germ-line mutation carriers with ovarian and breast cancer.
F1000 Biology Reports. 2-10, 2010.
[Journal]
22)  Annunziata CM, Bates SE.
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.
F1000 Biol Rep. 2, 2010.
[Journal]
23)  Annunziata CM, O'Shaughnessy J.
Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer.
Clin. Cancer Res. 16: 4517-26, 2010.
[Journal]
24)  Driscoll JJ, Pelluru D, Lefkimmiatis K, Fulciniti M, Prabhala RH, Greipp PR, Barlogie B, Tai YT, Anderson KC, Shaughnessy JD, Annunziata CM, Munshi NC.
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.
Blood. 115: 2827-34, 2010.
[Journal]
25)  Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, Calvo K, Choyke P, Kimm D, Steinberg SM, Kohn EC.
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Clin. Cancer Res. 16: 664-72, 2010.
[Journal]
26)  Annunziata C, Minasian L, Kohn E.
Early Diagnosis. In: 100 Key Questions on Ovarian Cancer.
Barcelona: P Permanyer SL; 2009. p. 1-12 [Book Chapter]
27)  Annunziata CM, Kotz HL.
Uterine papillary serous carcinoma: a new paradigm for treatment?.
Cancer. 115: 3594-6, 2009.
[Journal]
28)  Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC.
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
J. Clin. Oncol. 26: 3709-14, 2008.
[Journal]
29)  Azad NS, Annunziata CM, Steinberg SM, Minasian L, Premkumar A, Chow C, Kotz HL, Kohn EC.
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Cancer. 112: 1726-32, 2008.
[Journal]
30)  Annunziata CM, Azad N, Dhamoon AS, Whiteley G, Kohn EC.
Ovarian cancer in the proteomics era.
Int. J. Gynecol. Cancer. 18 Suppl 1: 1-6, 2008.
[Journal]
31)  Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T.
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.
Cell Cycle. 7: 940-9, 2008.
[Journal]
32)  Annunziata CM, Kleinberg L, Davidson B, Berner A, Gius D, Tchabo N, Steinberg SM, Kohn EC.
BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer.
Clin. Cancer Res. 13: 6585-92, 2007.
[Journal]
33)  Kohn EC, Azad N, Annunziata C, Dhamoon AS, Whiteley G.
Proteomics as a tool for biomarker discovery.
Dis. Markers. 23: 411-7, 2007.
[Journal]
34)  Azad NS, Rasool N, Annunziata CM, Minasian L, Whiteley G, Kohn EC.
Proteomics in clinical trials and practice: present uses and future promise.
Mol. Cell Proteomics. 5: 1819-29, 2006.
[Journal]
35)  Annunziata CM, Kohn EC.
Is there a genomic basis for primary chemoresistance in ovarian cancer?.
Gynecol. Oncol. 90: 1-2, 2003.
[Journal]
36)  Moscarillo FM, Annunziata CM.
ECT in a patient with a deep brain-stimulating electrode in place.
J ECT. 16: 287-90, 2000.
[Journal]
37)  Annunziata CM, Safiran YJ, Irving SG, Kasid UN, Cossman J.
Hodgkin disease: pharmacologic intervention of the CD40-NF kappa B pathway by a protease inhibitor.
Blood. 96: 2841-8, 2000.
[Journal]
38)  Cossman J, Annunziata CM, Barash S, Staudt L, Dillon P, He WW, Ricciardi-Castagnoli P, Rosen CA, Carter KC.
Reed-Sternberg cell genome expression supports a B-cell lineage.
Blood. 94: 411-6, 1999.
[Journal]
39)  Messineo C, Jamerson MH, Hunter E, Braziel R, Bagg A, Irving SG, Cossman J.
Gene expression by single Reed-Sternberg cells: pathways of apoptosis and activation.
Blood. 91: 2443-51, 1998.
[Journal]
40)  Cossman J, Messineo C, Bagg A.
Reed-Sternberg cell: survival in a hostile sea.
Lab. Invest. 78: 229-35, 1998.
[Journal]
41)  Messineo C, Coupland R, Bakhshi A, Raffeld M, Irving SG, Bagg A, Cossman J.
Rearrangement, hypermutation, and possible preferential use of a VH5 gene, VH32, in a Hodgkin's cell line.
Hematopathology and molecular hematology. 11: 19-28, 1997.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 6/16/2014.